The ability of topoisomerase II inhibitor, teniposide, to induce aneuploidy and meiotic delay in somatic and germinal cells of male mice was investigated by fluorescence in situ hybridisation (FISH) assay using labelled DNA probes and 5-bromo-2#-deoxyuridine (BrdU) incorporation assay, respectively. Colchicine and mitomycin C were used as a positive control aneugen and clastogen, respectively, and these compounds produced the expected responses. Using FISH assay with centromeric and telomeric DNA probes for erythrocyte, micronuclei (MN) showed that teniposide is not only clastogenic but also aneugenic in somatic cells in vivo. The assay also showed that chromosomes can be enclosed in the MN before and after centromere separation. By using the BrdU incorporation assay, it could be shown that the meiotic delay caused by teniposide in germ cells was $48 h. Disomic and diploid sperms were shown in epididymal sperm hybridised with DNA probes specific for chromosomes 8, X and Y after teniposide treatment. The prevalence of autodiploid (XX88 and YY88) sperm and disomic XX8 or YY8 sperm indicates that the second meiotic division was more sensitive to teniposide than the first meiotic division. The results also suggest that earlier prophase stages contribute relatively less to teniposide-induced aneuploidy. Both the clastogenic and the aneugenic potential of teniposide can give rise to the development of secondary tumours and abnormal reproductive outcomes in cured cancer patients and medical personnel exposing to drug regimens that include teniposide. Thus, genetic counselling of these patients should take place before the start of chemotherapy and should take the present results into consideration.
Introduction
Type II topoisomerases are essential nuclear enzymes found in all living organisms (1) . Their basic role in cells is to catalyse the transport of one DNA double helix through a transient double-strand break in another DNA molecule. This activity helps relieve tensions built up in DNA during various DNA metabolic processes, such as DNA replication, chromosome condensation and decondensation, chromosome segregation and transcription (2) . Because of its essential role in cell growth, cell cycle, as well as the high expression in proliferating cells, this enzyme is an ideal target for cancer chemotherapeutic drug (3) . Virtually, every form of cancers that can be cured by systemic chemotherapy were always treated with regimens that focus on (or at least contain) drugs targeted to topoisomerase II (4) . Indeed, drugs targeted to topoisomerase II are now indispensable components of systemic chemotherapy schedule, which could effectively cure several known types of human cancers.
Teniposide is a podophyllotoxin derivative and was found to be able to increase the concentration of topoisomerase II-DNA cleavage complexes (3) . This action converts topoisomerase II to a potent cellular toxin that fragments the genome. Consequently, teniposide is referred to as a topoisomerase II poison. It has been known for more than a decade that teniposide stabilises topoisomerase II-associated doublestranded DNA breaks by inhibiting the ability of the enzyme to ligate cleaved nucleic acid molecules (4) . A pervious study that examined drug effects on human topoisomerase IIa indicated that podophyllotoxins action at both scissile bonds are required to stabilise double-stranded breaks in the genetic material (5) . The presence of podophyllotoxins at either scissile bond inhibits DNA ligation only on that strand and hence stabilises a single-stranded break in the double helix (5) . It has been shown that in the treatment against small cell lung cancer, malignant lymphoma, breast cancer and ovarian cancer etc. through both clinical findings from chemotherapy results and in vitro chemosensitivity test of tumour specimen, anti-tumour effect on teniposide was stronger than other chemotherapeutic drugs (6, 7) . However, podophyllotoxins utilisation is associated with an increased risk of secondary acute myeloid leukaemia and increased sperm frequencies with chromosomal abnormalities (8, 9) .
As with many other anticancer drugs, high doses of podophyllotoxins as etoposide and teniposide induce apoptosis and disruption of inner mitochondrial membrane potential (10, 11) . However, several lines of evidence indicate that low doses of various chemotherapeutic drugs are capable of inducing mitotic catastrophe, resulting from abnormal mitotic events that produce improper chromosomal segregation and cell division, leading to the formation of cells bearing mutations (12) . These cells can develop resistance to the therapeutic agents or may lead to the development of secondary tumours and abnormal reproductive outcomes. Chromosomal imbalance (aneuploidy) induced by aneugens is a phenomenon observed in .90% of all solid tumours. Even haematological cancers, known to have a rather stable chromosome number, frequently display loss or gain of few chromosomes (13) . Diploidy and aneuploidy in germ cells may cause abortions or children with congenital abnormalities such as trisomy 21, Klinefelter's or Turner syndromes, respectively (14) .
Teniposide has been reported to exert strong mutagenic effects in mammalian cells in vitro but not in bacteria (15) (16) (17) . It is a potent clastogenic agent in mouse lymphoma cell lines (17) and it has been reported to induce sister chromatid exchanges in CHO cells (18) . Exposure of V79 cells to different concentrations of teniposide resulted in a concentrationrelated elevation in the frequency of micronucleated binucleate cells (19) . Teniposide induced chromosomal aberrations, aneuploidy and micronucleus formation in CHO cells (20, 21) . The drug also induced sister chromatid exchange in V79 cells and mutation and somatic recombination in Drosophila melanogaster in the wing spot test (22, 23) . Despite podophyllotoxin's increasing use in malignancies, scarce data are available in literature on its potential aneugenicity in vivo. In an effort to predict patients' reaction to tumour therapy, the present study was designed to evaluate the aneugenicity of teniposide in somatic and germinal cells of male mice in vivo. The bone marrow micronucleus test complemented by fluorescence in situ hybridisation (FISH) assay was performed in mouse bone marrow cells to determine the aneugenic and clastogenic origin of induced micronuclei (MN). The 5-bromo-2#-deoxyuridine (BrdU) incorporation assay was used to test if teniposide treatment altered the duration of the meiotic divisions and the sperm-FISH assay was performed for aneugenicity induction during male meiosis. In order to determine the reliability of the methods, two model mutagens, colchicine and mitomycin C, known to be predominantly aneugenic and clastogenic, respectively, were used as positive control substances.
Materials and methods

Animals
Adult male white Swiss albino mice weighing 23-27 g (10-12 weeks old) were obtained from Experimental Animal Care Center at our university. The animals were maintained in an air-conditioned animal house at a temperature of 25-28°C, relative humidity at $50% and photocycle of 12:12 h light and dark periods. The animals were provided with standard diet pellets and water ad libitum. All experiments were carried out according to the Guidelines of the Animal Care and Use Committee at our university. Each treatment group and vehicle control group consisted of five randomly assigned animals. The total number of animals in the somatic cell study was 15 treated mice and 5 vehicle control whereas the total number of animals in the germ cell studies was 60 treated and 35 vehicle control mice.
Drugs and treatment
Teniposide (Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA) was dissolved in dimethyl sulfoxide (DMSO) in sterile dH 2 O, mixed on a magnetic stirrer for at least 30 min prior to administration and administered by intraperitonial injection within 1 h following preparation. Colchicine and mitomycin C (Sigma Chemical St Louis, MO, USA) were dissolved in sterile water and were used as a positive control aneugen and clastogen, respectively. Control mice receiving equal amount of DMSO (15% DMSO in single treatment or 2% in multiple treatment) was included in order to code the slides and avoid scoring biases. The injected volume was 0.1 ml/10 g body weight. All other chemicals were of the finest analytical grade.
Bone marrow conventional micronucleus test Animals were treated with 0.5 mg/kg teniposide and bone marrow was sampled 24 h after treatment. The dose of teniposide was selected based on the data of Bakheet et al. (24) . Colchicine and mitomycin C were used as a positive control aneugen and clastogen, respectively, at the dose of 2 mg/kg each (25) . Bone marrow smears were prepared and stained with May-Gruenwald/Giemsa solutions (26) . At least four slides were made for each animal and allowed to dry overnight. One slide per animal was stained with May-Gruenwald/Giemsa solutions for conventional assessment of the MN frequencies in polychromatic erythrocytes (PCEs) and normochromatic erythrocytes (NCEs). The remaining unstained slides were stored at À20°C for the distinction between the clastogenic and aneugenic effects by identifying the origin of MN with the mouse DNA probes. Per animal, 1000 PCE of coded slides were scored for the presence of MN. In addition, the number of PCEs among 1000 NCE per animal was recorded to evaluate bone marrow suppression and mitotic activity was calculated as %PCE 5 [PCE/(PCE þ NCE)] Â 100.
Bone marrow FISH analysis of MN using centromeric and telomeric DNA probes Two DNA probes were used for tandem labelling: a murine minor satellite DNA probe specific for the centromeric region (27) and a murine hexamers DNA probe specific for the telomeric region (28) . The centromeric and telomeric probes were labelled with the fluorescent dyes Cy3 and fluoresceinisothiocyanate (FITC) using the biotin or digoxygenin systems according to the manufacturer's instructions (GIBCO Invitrogen, Carlsbad, CA, USA). In situ hybridisation assay was performed as described elsewhere (29) (30) (31) (32) with slight modifications. Briefly, frozen slides were brought to room temperature and rehydrated in 2Â saline sodium citrate buffer (SSC) buffer for 5 min prior to treatment with 0.1% Triton X-100 in 2Â SSC for 3 min. After washing the slides in 2Â SSC for 2 min, they were fixed in 4% paraformaldehyde for 10 min at room temperature and washed again in 2Â SSC for 3 min. Then, the slides were denaturated for 10 min in 70% formamide at 78°C and dehydrated in an ice-cold ethanol series of 70, 90 and 100% for 2 min each. After airdrying, the slides were brought to 37°C for ,3 min on a slide warming plate prior to mixing with the denaturated hybridisation mix. The hybridisation mix contained 20 parts of the master mix 1.0 (50% formamide and 10% dextran sulphate), 2 parts of centromeric probe ($20 ng per slide), 2 parts of telomeric probe ($12 ng per slide), 3 parts of herring sperm DNA (500 lg/ml) and 3 parts of distilled water. The hybridisation mix was denatured for 5 min at 78°C and chilled on ice. Aliquots of 30 ll of the hybridisation mix were added to each slide, covered with coverslip and sealed with rubber cement. Hybridisation was carried out overnight in a moist chamber at 37°C.
Post-hybridisation washing consisted of two steps: 40 min in 50% formamide at 45°C and two washes for 15 min at 37°C in phosphate-nonidet P-40 (PN) buffer (0.1 M sodium phosphate, 0.1% Nonidet P40, pH 8.0). After incubation with 40 ll PNBR (PN buffer plus 5% blocking reagent and 0.02% sodium azide) for 10 min, the hybridised probes were detected by streptavidinCy3 for the biotin-labelled centromeric DNA probe and anti-digoxigenin-FITC for the digoxigenin-labelled telomeric DNA probe. The hybridisation signals were amplified by two rounds of incubation with biotinylated anti-streptavidin followed by streptavidin-Cy3 and FITC-labelled anti-sheep IgG antibody made in rabbit. The cells were counterstained with 4,6-diamidino-2-phenylindole [DAPI; 0.1-0.5 lg/ml in phosphate-buffered saline (PBS)] for 10 min at room temperature and coverslipped in Vectashield mounting medium. The slides were scored immediately or following storage for several days at 4°C in the dark. The two applied DNA probes are identified by the regular appearance of a red domain for centromeric DNA probe (labelled with Cy3) and a green domain for the telomeric DNA probe (labelled with FITC). Strict scoring criteria were applied to avoid misinterpretation of signal numbers. MN were scored as having two or more domains of the same colour if the signals were (i) nearly similar in size and intensity, (ii) separated by at least the distance of half the diameter of the domain and (iii) regular in appearance, not diffuse and clearly positioned within the MN. For signal detection, 50-150 MN per group were examined for the presence or absence of DNA probes and the numbers of signals per MN were counted under an Axioplan Fluorescence Microscope.
Sperm BrdU incorporation assay
The time of development from meiotic divisions in spermatocytes to epididymal sperm was assessed by labelling cells with BrdU. Mice were injected with 100 mg/ kg BrdU in order to label spermatocytes at S-phase during preleptotene of meiosis. During meiosis I and II, 13 days later, the mice were treated with 24 mg/kg teniposide. For human chemotherapy, teniposide is administered typically at doses of 30-50 mg/m 2 /day for 5 days or three doses of $200 mg/m 2 over 7 days. The mouse has a body weight/surface area ratio of $3 kg/m 2 . Thus, the dose of 24 mg/ kg used in the current study corresponds to $72 mg/m 2 and is within the dose range used for human chemotherapy. Five treated and five solvent control mice were sacrificed per day 33-37 after BrdU injection (20-24 days after drug treatment).
Both Caudae epididymes from each male were isolated and several incisions were made. The epididymes were then placed in eppendorf cups with 300 ll of foetal calf serum and the sperms were allowed to actively leave the epididymes for 60 min at 37°C. Sperm suspensions (7 ll) were pipetted onto one end of a clean dry glass slide and spread across the slide (33) . Decondensation of the sperm heads was performed by incubation of the coded slides in 10 mM dithiothreitol for 30 min on ice followed by incubation in 4 mM lithium 3,5-diiodosalicylic acid for 60 min at room temperature. The slides were denatured in 2N HCl at room temperature for 60 min and washed two times for 10 min in a Coplin jar with PBS at room temperature to neutralise the acid. Immunodetection was carried out in two steps in a humidified chamber: slides were incubated with 40 ll per slide of a rat anti-BrdU (Seralab, 1/100) antibody for 30 min at room temperature. After washing for 10 min with PN buffer at room temperature, the slides were incubated with 40 ll per slide of a FITC-conjugated anti-rat IgG antibody (Dianova, 1/100) for 30 min at room temperature and washed again for 10 min in PN buffer at room temperature. Propidium iodide (2 lg/ml) was used as counterstaining. Averages of 10 000 BrdU-positive and BrdU-negative cells per animal were blind scored under a Fluorescence Microscope.
Sperm multicolour FISH assay
Random groups of five mice each were treated with single doses of 6, 12 and 24 mg/kg teniposide. Colchicine was used as a positive control aneugen at the dose of 3 mg/kg (34) . After drug administration, the animals were maintained with food and water ad libitum until being sacrificed. Mice were sacrificed by cervical dislocation 23 days after drug treatment. In order to determine if subacute treatment would have an effect because prophase stages would be included in teniposide treatment, doses of 0.5, 1 and 2 mg/kg of teniposide in 2% DMSO were injected on 12 consecutive days and sperms were sampled 23 days after the last treatment. Immediately after animal sacrificing, the sperm were collected from the C. epididymis. The time of sampling was chosen on the basis of the BrdU incorporation study.
The frequencies of disomic and diploid sperm were determined by FISH with DNA probes specific for mouse chromosomes 8 (35), X (36) and Y (37). The probes for chromosomes 8 and Y were labelled with the fluorescent dyes Cy3 and FITC using the biotin or digoxygenin systems, respectively, while the chromosome X probe was labelled with a combination of Cy3 and FITC using the biotin and digoxygenin systems according to the manufacturer's instructions (GIBCO Invitrogen, Carlsbad, CA, USA). The probe mixture [4.5 lg probes in 2.1. master mix (55% formamide, 10% dextran sulfate) 2Â SSC] was denatured at 78°C for 10 min and chilled on ice. Hybridisations with fluorochrome-labelled DNA probes were performed as previously described by Attia et al. (34) with some modifications. Briefly, the sperm heads were decondensed as described above in BrdU incorporation assay and then the slides were denaturated for 10 min in 70% formamide at 78°C and dehydrated in ethanol series. Following the application of 30 ll of probe mixture, hybridisation was performed at 37°C for 24-48 h in a moist chamber. Posthybridisation washing and detection of the hybridised probes were performed as described above in bone marrow FISH analysis. Sperm nuclei were counterstained with 0.05-0.1 lg/ml DAPI. Slides were examined for disomic and diploid sperm under an Axioplan Fluorescence Microscope. Per animal, fluorescent signals from coded slides were counted in $10 000 sperms and sperms were designated as normal (X8 and Y8), disomic (X88, Y88 and XY8) or diploid (XY88, XX88 and YY88).
Statistical analysis
Data were expressed as the mean AE standard deviation (SD) of the means. The analysis parameters were tested for homogeneity of variance and normality and were found normally distributed. The data were, therefore, analysed by employing non-parametric tests, the Mann-Whitney U-test. Results were considered significantly different if the P value was 0.05.
Results
Bone marrow conventional MN test
The incidences of micronucleated polychromatic erythrocyte (MNPCE) in each treatment group as well as the PCE/NCEs ratio are shown in Table I . After treatment with the positive controls colchicine and mitomycin C, a statistically significant increase in the incidence of MNPCE over the control value was observed (P , 0.01). Moreover, mitomycin C significantly decreased the percent PCE (P , 0.05), indicating a reduction in erythroblast proliferation. Teniposide significantly increased MNPCE frequencies (P , 0.01) and the response was directly correlated with bone marrow toxicity as significant suppression of bone marrow was noted (P , 0.05). In NCEs, the MN frequencies were between 0.02 and 0.06/100 NCE in all groups. Thus, no discrimination between MN induced in PCE and NCE was required for the fluorescent analysis of MN with in situ hybridisation since the NCE only contributed minimally to the total number of MN.
Bone marrow FISH analysis of MN using centromeric and telomeric DNA probes The results for double labelling with centromeric and telomeric probes in both PCE and NCE are shown in Table II . The telomere-positive MN without a centromere signal represents MN containing an acentric fragment with pericentric heterochromatin. All MN with centromeric signals also had telomeric signals and these MN contained entire chromatids or entire chromosomes. After treatment of mice with the positive control aneugen colchicine, the majority of induced MN were telomere-as well as centromere positive, reflecting the expected aneugenic effects of colchicine. After treatment of mice with the positive control clastogen mitomycin C, only 19.27% of induced MN were double-labelled with the telomere and the centromere probes, confirming the predominantly clastogenic effects of mitomycin C. As shown in Figure 1 and Table II , the ratios of MN arising from clastogenic (centromere negative) and aneugenic (centromere positive) effects of the vehicle and positive controls were found to be in the same range as reported earlier (29) (30) (31) (32) . With teniposide, 18.24% of the analysed MN had no signal, 35.14% showed telomere signals and 46.62% were double labelled with the telomere and the centromere probes. The distribution of the signal frequencies in MN that were positive only with the telomere probe is shown in Table III . The majority of analysed MN in (Figure 1 ). For example, after treatment with colchicine, 1.06% MNPCE were found in the conventional MN test and 88.75% MN were signals positive in the FISH analysis; thus, 0.94075% of the 1.06% MNPCE were calculated to be signals positive and, correspondingly, 0.11925% MN were calculated to be signals negative.
Sperm BrdU incorporation assay
The results of the BrdU incorporation assay are presented in Figure 2 . With 24 mg/kg of teniposide, prolongations of the duration of the meiotic divisions were observed. On days 21 and 22, the frequencies of BrdU-labelled sperm in the teniposide groups were significantly below the control values (P , 0.05 and P , 0.01, respectively), while on days 23 and 24, there were no significant differences between the teniposide-treated and control animals. According to Oakberg (38) , the development from meiotic spermatocytes of mice to epididymal sperm takes 22 days. Thus, the meiotic delay caused by teniposide was $48 h. Therefore, the optimum day for sperm sampling in the sperm-FISH assays was concluded to be 23 or 24 with teniposide.
Multicolour sperm-FISH assay
The results of the analysis of aneugenic effects in germ cells of male mice after single exposure to teniposide are presented in Table V , together with the negative and positive control data. Sex ratios were found to be in the same range as the theoretical ratio of 1:1 for X-versus Y-bearing sperm in all groups. A significant increase in the frequency of diploid sperm was caused by treatment with all doses of teniposide compared with the control value. Treatment of mice with 6 mg/kg of teniposide did not induce significant increases in disomic sperm; however, treatment with 12 and 24 mg/kg of teniposide significantly induced disomic sperm compared with the control value. The dose-response curves for teniposide-induced disomic and diploid sperm can be described by the linear equations y 5 0.004x þ 0.041 (r 2 5 0.990) and y 5 0.002x þ 0.003 (r 2 50.998), respectively ( Figure 3 ). The frequency of disomic sperm induced by colchicine was significantly increased by a factor of 1.64 compared with the control value. However, in contrast to teniposide, colchicine did not significantly increase the frequency of diploid sperm, indicating that no complete meiotic arrest occurred.
The results of the multiple exposures to teniposide are shown in Table VI . There were no mortality or symptoms of toxicity observed after repeated treatment with teniposide or the vehicle. These results indicate that repeated treatment with teniposide and the vehicle are well tolerated by experimental animals. Treatment of mice with 0.5 and 1 mg/kg of teniposide on 12 consecutive days did not induce any significant increases of disomic or diploid sperm. However, the highest dose group (2 mg/kg/day), which received a total of 24 mg/kg, induced significant increases in disomic and diploid sperm compared with the corresponding control values. The dose-response curves for teniposide-induced disomic and diploid sperm can be described by the linear equations y 5 0.017x þ 0.048 (r 2 5 0.838) and y 5 0.011x þ 0.001 (r 2 50.936), respectively ( Figure 4 ).
Discussion
The genotoxic activity of teniposide during mitosis in vivo was recently confirmed in our laboratory with the bone marrow MN test (24) . So far the origin of the teniposide-induced MN is not determined yet and there are no in vivo published aneuploidy studies for teniposide in germ cells. Therefore, the current study was designed to investigate the ability of teniposide to induce aneuploidy in somatic and germinal cells of male mice. The conventional bone marrow MN test complemented by FISH with the mouse centromeric and telomeric DNA probes was used to investigate the mechanisms of induction of MN in mice treated with teniposide. This assessment is particularly important for chemical clastogens, which may also have aneugenic potential. Such chemicals may interact, on the chromosomal level, with the respective targets for chromosomal missegregation. To determine the efficiency of the method, two model mutagens, colchicine and mitomycin C, known to have aneugenic and clastogenic actions, respectively, were used. The observed results of the MNPCE and the distribution of signals per MN in the solvent control and the two positive mutagens in the current study correspond well with the published data reported earlier (29, 32) . These data confirmed the sensitivity of the experimental protocol followed in the detection of genotoxic effects.
Teniposide at a dose of 0.5 mg/kg significantly increased the frequency of MNPCE, as expected (24) . Additionally, teniposide significantly decreased the percent PCE, indicating a reduction in erythroblast proliferation most likely by mitotic arrest. A total of 148 MN from teniposide-treatment group were analysed by FISH and 69 (46.62%) MN of these were double labelled with centromere and telomere probes, indicating that they were formed by lagging chromosomes and reflecting an aneugenic activity of teniposide. Similarly, 77 (53.38%) of the induced MN were centromere negative, indicating that they were formed by acentric fragments and reflecting the clastogenic activity of teniposide. Since the centromere probe labelled mitotic chromosomes at both chromatids, it can be concluded that equal proportions of MN contained single chromatids (chromosome loss) and biarmed chromosomes (non-disjunction).
These results indicate that teniposide is clastogenic and aneugenic during mitotic phases. Both the clastogenic and the aneugenic potential of teniposide in somatic cells can give rise to the development of secondary tumours. Therefore, the clinical use of this genotoxic drug must be weighed against the risks of secondary malignancies in cured patients. Importantly, experimental observations have shown that the catalytic topoisomerase II inhibitor, dexrazoxane, is able to enhance the cytotoxic action of teniposide (39) and modulates teniposide-induced DNA damage and apoptosis in the bone marrow cells in vivo (24) . Thus, based on the results of these previous in vivo studies, strategies can be developed to decrease the teniposide-induced genotoxicity in non-tumour cells using dexrazoxane. A total of 35.14% of the analysed MN was telomere positive and must be interpreted as MN harbouring terminal acentric fragments (Table III) . Additionally, 18.24% of the analysed MN had no FISH signals and must be interpreted as MN harbouring interstitial acentric fragments (Table II) . Centromere plus telomere doublelabelled MN that gave one centromeric signal and two telomere signals (Table IV) probably contained a chromosome lagging after centromere separation. MN with two centromere signals and four telomere signals most likely contained a chromosome lagging before centromere separation or two chromatids after centromere separation.
Studies in humans have shown that certain chemotherapy regimens increase the frequencies of aneuploidy in germinal cells (40) (41) (42) (43) , suggesting that such patients may be at higher risk for the development of secondary tumours and abnormal reproductive outcomes. Therefore, it is of general concern to decrease the risk of aneuploidy production, detection of germ cell aneugens and understandings of the causal mechanisms are essential. In the current study, aneuploidy was determined in germinal cell by the sperm-FISH assay. In order to determine the reliability of the methods, colchicine, known to be predominantly aneugenic, was used as positive control substance and the results of the positive and negative control were in the same range as those of the earlier studies (32, 34, 44, 45) . These data confirmed the sensitivity of the experimental protocol followed in the detection of aneuploidogenic effects. It has been often discussed that chemicals with aneugenic properties can alter the progression of cell division in both meiotic and mitotic cells (46, 47) . In the present study, the time of development from meiotic divisions in spermatocytes to epididymal sperm was assessed by the BrdU incorporation assay. The results clearly indicate that teniposide prolonged the duration of the meiotic divisions in mouse spermatocytes for 48 h. These observations therefore confirm previous results that inhibition of topoisomerase II function during different phases of the cell cycle by teniposide slow down cell cycle progression and causes cells to arrest at the G 2 /M phase (11, 48, 49) . Such G 2 /M arrest has been proposed to be due to induction of G 2 checkpoint machinery that allows damaged DNA to be repaired before cells move to the next cell cycle stage (50) .
In the present experiments, teniposide caused dose-dependent significant increases in the frequencies of disomic and diploid sperm. The induction of aneuploidy showed linear doseresponses between 0 and 24 mg/kg of teniposide. This in vivo observation is in line with an earlier in vitro report on the CHO cells that teniposide induces the formation of quadriradial chromosomes (21) . Polyploidy induced by teniposide was also demonstrated by flow cytometry techniques in murine erythroleukemic cells (48) . Furthermore, Morse-Gaudio and Risley (51) reported that incubation of isolated spermatogenic cells Xenopus laevis with teniposide led to dose-dependent induction of DNA breaks in all spermatocytes and spermatid stages to nuclear elongation stages, as analysed by alkaline single-cell gel electrophoresis. To determine if subacute treatment with low doses of teniposide would have an effect because earlier prophase stages would be included in teniposide treatment. Individual doses of 0.5, 1 and 2 mg/kg of each compound were injected on 12 consecutive days and sperms were sampled 23 days after the last treatment with teniposide. It was found that a total of 24 mg/kg teniposide applied to the entire prophase of meiosis significantly increased disomic and diploid sperm frequencies, while a total dose of 6 or 12 mg/kg was negative. In contrast, a single dose of 6 mg/kg teniposide applied to spermatocytes during the first meiotic division (meiosis I; MMI)/the second meiotic division (meiosis II; MMII) gave a positive result. These data suggest that earlier prophase stages contribute relatively less to teniposide-induced aneuploidy in male germ cells.
The sperm-FISH assay for disomy or diploidy is capable of detecting effects induced during both meiotic divisions and to compare the sensitivity of both meiotic divisions (52, 53) . In the current study, it was found that teniposide caused noticeable increases above the control of autodiploid sperm (XX88 and YY88). After treatment with teniposide, autodiploid sperm resulting from arrest of MMII were more frequent than diploid sperm resulting from arrest during MMI (XY88). Thus, the second meiotic division was more sensitive to teniposide treatment than the first meiotic division. The conclusion that second meiotic divisions were more sensitive to teniposide treatment than the first meiotic divisions is also supported by the observed frequencies of sex chromosome disomic. Sperm with signals of XX8 or YY8 were more frequent than sperm with signals of XY8. The data of sperm study indicate that male cancer patients receiving chemotherapy with teniposide may stand a higher risk of siring chromosomally abnormal offspring, i.e. with Down, Klinefelter or Turner syndromes. The chemotherapy with teniposide may also reduce the fertility of the patients. The most sensitive period of spermatogenesis to aneuploidy induction is meiosis. In humans, the time of development from meiosis in spermatocytes to mature sperm takes 40-57 days (38) with some uncertainty about the retention of sperm in the epididymis. Baumgartner et al. (54) could show that the aneuploidy rates in sperm of Hungarian men were elevated significantly 40-50 days after attempted suicide with diazepam and returned to control levels when sperm were sampled 100 days after the intoxication. Therefore, the hazard for patients to foster a chromosomally unbalanced child is only elevated during 3-4 months after the end of chemotherapy with aneugenic drugs. Often, cancer patients facing a limited life expectancy express a great desire to have a child. Genetic counselling of these patients should take place before the start of chemotherapy and should take the present results into consideration.
The present mouse bone marrow MN studies showed that exposure to 0.5 mg/kg teniposide yielded a significant increase in MNPCE. However, in the sperm-FISH assay, it was found that the lowest positive dose, which caused disomic or diploid sperm, was 6 mg/kg of teniposide. This observation suggests that MN in bone marrow are induced at lower doses than disomies or diploidies in sperm; hence, the bone marrow is the more sensitive tissue. It must of course be noted that the assays measure different end-points. Chromosome loss and breakage are measured in the MN test, and non-disjunction is detected in the sperm-FISH assay. Therefore, the present data confirm the general paradigm of hazard assessment that the positive outcome of the bone marrow MN test is an indicator of the genotoxic potential of a compound in germ cells. However, to quantify aneuploidy induced in germ cells is important for risk assessment purposes. Taking into account the fundamental differences between the meiotic process and the mitotic process, e.g. requirement for chromosome pairing, formation of chiasmata to allow recombination, prolonged duration of meiosis in oocytes (55) , it will always be necessary to confirm the aneugenic potential of a chemical detected in in vitro by studies in somatic and in germinal cells in vivo. Theoretically, the differences in cell biology may give rise to qualitative differences in response of germ cells and somatic cells to aneugens and the possibility of unique germ cell aneugens should not be neglected.
DNA topoisomerase inhibitors have a clear tendency to cause stranded DNA breaks, which primarily result in the formation of centromere-negative MN (32) . Similarly, the demonstration that teniposide is effective topoisomerase inhibitor suggests that teniposide elicit its clastogenic effects through this mechanism. Teniposide metabolites could also activate cells to enhance their intracellular production of reactive oxygen species, of which the stable and diffusible forms could damage nuclear DNA (56) . If the cellular repair mechanisms are overloaded, primary DNA damage may lead to structural or numerical chromosomal aberration and eventually cause tumours (57) . However, the induction of centromerepositive MN by teniposide indicates that there may be another mechanism through which teniposide can induce its genotoxic effect, an observation that also underscores the importance of using the FISH modification of the MN assay to determine the origin of the induced MN. The possible mechanism by which teniposide may exert its aneugenic effect is through inhibition of topoisomerase II which could result in a mal-segregation of chromosomes during cell divisions. As mentioned in Introduction, topoisomerase II has been demonstrated to be necessary for the proper separation of sister chromatids during cell divisions (2) with both non-disjunction and breakage occurring in its absence (58) . Thus, teniposide may be able to inhibit two key roles of topoisomerase II, its ability to properly segregate newly replicated chromosomes as well as its function to religate transient double-stranded DNA breaks.
In summary, by using FISH assay with centromeric and telomeric DNA probes for erythrocyte MN, it could be shown that teniposide is not only clastogenic but also aneugenic in somatic cells in vivo. The assay also showed that chromosomes can be enclosed in an MN before and after centromere separation. By using the BrdU incorporation assay, it could be shown that the meiotic delay caused by teniposide was $48 h. With the sperm-FISH analysis, it could be shown that teniposide induce aneuploidies during meiosis that result in disomic sperm as well as complete meiotic arrest that results in diploid sperm. The prevalence of autodiploid (XX88, YY88) sperm and disomic XX8 or YY8 sperm indicate that the second meiotic division was more sensitive to teniposide than the first meiotic division. The results suggest also that earlier prophase stages contribute relatively less to teniposide-induced aneuploidy. Both the clastogenic and the aneugenic potential of teniposide can give rise to the development of secondary tumours and abnormal reproductive outcomes in cancer patients and medical personnel exposing to drug regimens that include teniposide. The results of the current study and our previous data base show that the aneuploidy assays such as the sperm-FISH assay and MN test complemented by FISH with centromeric DNA probes have been sufficiently validated to be recommended for the assessment of aneugenic effects of chemicals. 
